CVC Capital Partners Plc is actively seeking co-investors to help finance its proposed acquisition of Italian drugmaker Recordati SpA, aiming to secure €10.9 billion ($12.7 billion) for the deal, according to sources familiar with the matter. This significant funding requirement underscores the scale of CVC's ambition to expand its healthcare portfolio through a major European acquisition. The move signals CVC's intent to leverage its substantial resources, potentially involving strategic partnerships to share the financial burden and risk associated with such a large transaction. Recordati, a company with a market capitalization reflecting its niche position in the pharmaceutical sector, represents a key target for CVC's growth strategy in the competitive global drug market.